Michigan Institute of Urology

Joshua Palka, DO, reflects on the key trends that shaped urologic oncology in 2025, emphasizing the growing role of precision medicine across disease states.

One particularly striking finding from KEYNOTE-905/EV-303 is the nearly 60% pathologic complete response rate.

Jason M. Hafron, MD, CMO, touches on the growing shift toward biomarker-driven therapy in advanced prostate cancer.

Jason M. Hafron, MD, recaps noteworthy prostate cancer research from ESMO 2025.

Jason M. Hafron, MD, CMO, reflects on the most impactful recent developments in prostate cancer and offers insight into where the field is headed.

Ambulatory surgery centers were evaluated based entirely on objective, risk-adjusted measures of their patients’ outcomes.

"I think AI is going to have a significant role. We're just at the tip of the iceberg," says Jason M. Hafron, MD, CMO.

Michigan Institute of Urology is a clinical trial site for LEGION-100.

The panel concludes by offering key takeaways on the evolving treatment landscape for BCG-unresponsive non–muscle invasive bladder cancer.

Experts on non–muscle invasive bladder cancer discuss promising developments in the overall treatment landscape, highlighting potentially practice-changing clinical research.

Bladder cancer specialists discuss their strategies for monitoring patients with BCG-unresponsive non–muscle invasive bladder cancer.

A panel of experts provide clinical insights on factors that inform how they select treatments for patients with BCG-unresponsive non–muscle invasive bladder cancer.

"Looking at data, if you apply IsoPSA in a consistent manner, based on the studies published, you'll see up to a 55% reduction in unnecessary biopsies," says Jason M. Hafron, MD.

Experts on bladder cancer discusses strategies to minimize adverse effects and the role of immunotherapy in BCG-unresponsive NMIBC treatment paradigms.

Bladder cancer experts discuss quality of life and progression considerations and their impact on treatment decisions for patients with BCG-unresponsive NMIBC.

“Again, the importance of this paper to clinical practice is that it gives us real numbers on what the likelihood is of cancer in those patients with PI-RADS 3 or less,” says Jason M. Hafron, MD.

Jason Hafron, MD, CMO, provides an overview of the QUILT trial investigating N-803 in patients with BCG-unresponsive high-grade non–muscle invasive bladder cancer.

The panel reviews data from the SunRISe-1 trial investigating TAR-200 and offers its impressions on the efficacy and safety findings.

Bladder cancer experts discuss the evolving treatment landscape in BCG-unresponsive NMIBC and give an overview of TAR-200, an emerging therapy.

A panel of experts on non–muscle invasive bladder cancer (NMIBC) discuss challenges associated with BCG shortages and the impact on treatment options and patients’ quality of life.

"At MIU, we host many ancillary services, including complete ultrasound services, UroCuff, urodynamics, PTNS [percutaneous tibial nerve stimulation], full laboratory and pathology services, Xofigo [radium-223]," says Jason M. Hafron, MD.

The center will offer a comprehensive range of treatments, including prostate artery embolization for men suffering from benign prostatic hyperplasia with very large prostates.

“Sexual wellness is critical to overall health and happiness. That’s why you see more men and women turning to specialty health clinics for solutions to problems they consider more aesthetic versus medical,” said Mitchell Hollander, MD.

An exclusive Urology Times survey measured US-based urologists’ uptake, access to, and indications for utilizing prostate-specific membrane antigen-targeting agents.

"The purpose of the study is to compare the safety and efficacy of lutetium PSMA I&T vs standard of care hormone therapy in patients with metastatic castration-resistant prostate cancer," says Jason M. Hafron, MD.

"We have become more advanced over time. We understand that men's health is more than just testosterone. Men's health is more than just erectile function and prostate disease," says Michael D. Lutz, MD.

"What we noticed is that even though it's not in the NCCN guidelines, a lot of urologists are using oral Relugolix in combination with other prostate cancer medications in similar numbers to the injectables," says Jason M. Hafron, MD.

The TAVT-45 formulation of abiraterone acetate was created for patients with dysphagia, who would have difficulty swallowing a tablet.

In an interview during the 2022 LUGPA Annual Meeting, Jason M. Hafron, MD, shared advice on optimizing advanced prostate cancer clinics, recapped the biggest advances in urologic cancer treatment in 2022, and discussed how Jelmyto treatment for UTUC has evolved over time.